[{"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-001", "question": "A 14-month-old boy with genetically confirmed PMM2-CDG (p.Arg141His and p.Phe119Leu compound heterozygous variants) is scheduled for inguinal hernia repair. Preoperative coagulation studies show antithrombin III 45% (normal 80-120%), protein C 38% (normal 70-140%), and protein S 32% (normal 65-140%). All other labs are normal. What is the most appropriate perioperative management to minimize thrombotic risk?", "options": ["Proceed with surgery without prophylaxis; risk is theoretical", "Administer prophylactic enoxaparin 0.5 mg/kg subcutaneously 12 hours preoperatively and postoperatively", "Transfuse fresh frozen plasma to correct factor deficiencies before surgery", "Delay surgery indefinitely until coagulation factors normalize with nutritional support", "Administer antithrombin III concentrate 50 IU/kg immediately preoperatively"], "answer": "B", "answer_index": 1, "explanation": "PMM2-CDG causes combined antithrombin III, protein C, and protein S deficiency, creating significant thrombotic risk. For surgical prophylaxis, LMWH is recommended to address all deficient pathways. FFP provides insufficient correction and risks volume overload. ATIII concentrate alone doesn't address protein C/S deficiency. The thrombosis risk is not theoretical, with rates of 10-15% in moderate-severe cases.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 14‑month‑old with genetically confirmed PMM2‑CDG, markedly decreased antithrombin III, protein C, and protein S; scheduled for inguinal hernia repair; question explicitly asks for perioperative management to minimize thrombotic (not bleeding) risk. PMM2‑CDG is known to cause combined anticoagulant deficiencies and increased risk of venous thrombosis, particularly around surgery and central lines.\\nEvaluation of options: A is incorrect because thrombotic risk in PMM2‑CDG is documented and not merely theoretical. B (prophylactic enoxaparin) is appropriate standard VTE prophylaxis to counteract the prothrombotic state and is consistent with pediatric hematology practice in high‑risk settings. C (FFP) primarily treats clotting factor deficiency and is for bleeding/INR correction, not targeted VTE prophylaxis, and carries volume risk in an infant. D is unreasonable; these inherited deficiencies will not normalize with nutrition and delaying necessary hernia repair indefinitely is inappropriate. E (ATIII concentrate) addresses only antithrombin deficiency and leaves protein C/S deficiency unaddressed; moreover LMWH prophylaxis is the more standard strategy.\\nMain medical accuracy issue(s): None significant; item reflects current understanding of coagulation abnormalities in PMM2‑CDG and appropriate perioperative management.\\nMinimal fix: Specify that no history of prior VTE or bleeding exists to clarify typical prophylactic (not therapeutic) dosing context for LMWH.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 14‑month‑old with genetically confirmed PMM2‑CDG, markedly decreased antithrombin III, protein C, and protein S; scheduled for inguinal hernia repair; question explicitly asks for perioperative management to minimize thrombotic (not bleeding) risk. PMM2‑CDG is known to cause combined anticoagulant deficiencies and increased risk of venous thrombosis, particularly around surgery and central lines.\nEvaluation of options: A is incorrect because thrombotic risk in PMM2‑CDG is documented and not merely theoretical. B (prophylactic enoxaparin) is appropriate standard VTE prophylaxis to counteract the prothrombotic state and is consistent with pediatric hematology practice in high‑risk settings. C (FFP) primarily treats clotting factor deficiency and is for bleeding/INR correction, not targeted VTE prophylaxis, and carries volume risk in an infant. D is unreasonable; these inherited deficiencies will not normalize with nutrition and delaying necessary hernia repair indefinitely is inappropriate. E (ATIII concentrate) addresses only antithrombin deficiency and leaves protein C/S deficiency unaddressed; moreover LMWH prophylaxis is the more standard strategy.\nMain medical accuracy issue(s): None significant; item reflects current understanding of coagulation abnormalities in PMM2‑CDG and appropriate perioperative management.\nMinimal fix: Specify that no history of prior VTE or bleeding exists to clarify typical prophylactic (not therapeutic) dosing context for LMWH.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-002", "question": "A 3-year-old girl presents with opsoclonus-myoclonus syndrome and is found to have a right adrenal neuroblastoma with favorable histology, MYCN non-amplified. After tumor resection, neurologic symptoms persist despite high-dose steroids. Which immunotherapy targeting the specific B-cell mediated pathogenesis is most appropriate?", "options": ["Rituximab 375 mg/m² weekly for 4 weeks", "Cyclophosphamide 600 mg/m² monthly for 6 months", "Intravenous immunoglobulin 2 g/kg monthly", "Alemtuzumab 30 mg daily for 5 days", "Tocilizumab 8 mg/kg every 2 weeks"], "answer": "A", "answer_index": 0, "explanation": "Opsoclonus-myoclonus syndrome is mediated by anti-neuronal antibodies produced by B-cells. Rituximab depletes B-cells and is first-line for steroid-refractory cases. IVIG is adjunctive but not primary therapy. Cyclophosphamide is less specific and more toxic. Alemtuzumab is not standard and causes profound lymphodepletion. Tocilizumab targets IL-6, not the primary antibody-mediated pathogenesis.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 3‑year‑old with opsoclonus–myoclonus syndrome (OMS), adrenal neuroblastoma, favorable biology, persistent neurologic symptoms despite high‑dose steroids, and question explicitly asking for “immunotherapy targeting the specific B‑cell mediated pathogenesis.” OMS in neuroblastoma is widely accepted as an autoantibody/B‑cell–mediated paraneoplastic syndrome. Rituximab is a CD20 monoclonal antibody that selectively depletes B‑cells and is increasingly used for steroid‑refractory OMS.\\nOption analysis: A (rituximab) directly targets B‑cells and matches the described pathogenesis and steroid‑refractory setting. B (cyclophosphamide) is immunosuppressive but nonspecific, more toxic, and not the preferred targeted B‑cell therapy. C (IVIG) is immunomodulatory and used in OMS, but the stem asks for specific B‑cell–directed treatment and labels IVIG as adjunctive, making it less correct here. D (alemtuzumab) causes broad lymphocyte depletion and is not standard for OMS. E (tocilizumab) blocks IL‑6 and does not directly target autoantibody‑producing B‑cells.\\nMain logical/medical issues: Minor—some centers may prioritize IVIG or combination therapy, but rituximab as targeted B‑cell therapy is still the best fit. Minimal fix: Specify “recommended B‑cell–depleting biologic agent” in the stem to further distinguish it from IVIG or alkylators.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 3‑year‑old with opsoclonus–myoclonus syndrome (OMS), adrenal neuroblastoma, favorable biology, persistent neurologic symptoms despite high‑dose steroids, and question explicitly asking for “immunotherapy targeting the specific B‑cell mediated pathogenesis.” OMS in neuroblastoma is widely accepted as an autoantibody/B‑cell–mediated paraneoplastic syndrome. Rituximab is a CD20 monoclonal antibody that selectively depletes B‑cells and is increasingly used for steroid‑refractory OMS.\nOption analysis: A (rituximab) directly targets B‑cells and matches the described pathogenesis and steroid‑refractory setting. B (cyclophosphamide) is immunosuppressive but nonspecific, more toxic, and not the preferred targeted B‑cell therapy. C (IVIG) is immunomodulatory and used in OMS, but the stem asks for specific B‑cell–directed treatment and labels IVIG as adjunctive, making it less correct here. D (alemtuzumab) causes broad lymphocyte depletion and is not standard for OMS. E (tocilizumab) blocks IL‑6 and does not directly target autoantibody‑producing B‑cells.\nMain logical/medical issues: Minor—some centers may prioritize IVIG or combination therapy, but rituximab as targeted B‑cell therapy is still the best fit. Minimal fix: Specify “recommended B‑cell–depleting biologic agent” in the stem to further distinguish it from IVIG or alkylators.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-003", "question": "A 7-year-old girl with McCune-Albright syndrome (confirmed GNAS R201C mutation) presents with premature thelarche, vaginal bleeding, and a growth velocity of 12 cm/year. Bone age is 10 years. Which endocrine intervention specifically targets the underlying pathophysiology of precocious puberty in this condition?", "options": ["GnRH agonist (leuprolide) 7.5 mg IM monthly", "Aromatase inhibitor (letrozole) 2.5 mg daily", "Estrogen receptor antagonist (tamoxifen) 10 mg twice daily", "Progesterone-only contraceptive (medroxyprogesterone) 10 mg daily", "Ketoconazole 200 mg twice daily"], "answer": "B", "answer_index": 1, "explanation": "In McCune-Albright syndrome, precocious puberty results from autonomous ovarian hyperfunction, not central activation. GnRH agonists are ineffective because the process is gonadotropin-independent. Aromatase inhibitors block peripheral estrogen synthesis from autonomous follicular cysts. Tamoxifen is less effective and has more side effects. Progesterone doesn't address estrogen excess. Ketoconazole has significant toxicity.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 7-year-old girl with genetically confirmed McCune-Albright syndrome, peripheral (gonadotropin-independent) precocious puberty manifestations (premature thelarche, vaginal bleeding), advanced bone age, and explicit ask for an endocrine intervention that targets the *underlying pathophysiology* of precocious puberty in this condition.\\nMcCune-Albright causes constitutive Gsα activation and autonomous ovarian estrogen production; the pathophysiology of the precocious puberty is gonadotropin-independent estrogen excess. Aromatase inhibitors (e.g., letrozole) reduce estrogen synthesis from ovarian and peripheral sources and are standard targeted therapy in this context, making B the best choice.\\nA (GnRH agonist) targets central precocious puberty, which the stem and explanation emphasize is not the mechanism here. C (tamoxifen) blocks estrogen receptors but does not reduce estrogen production and is generally second-line with more side effects. D (progesterone) may control bleeding but does not address estrogen excess or bone age advancement. E (ketoconazole) can reduce steroidogenesis but is not standard due to toxicity.\\nMain medical issues: Dosing details are somewhat arbitrary but not misleading. Overall logic and teaching point are sound.\\nMinimal fix: Add a brief phrase “gonadotropin-independent (peripheral) precocious puberty” in the stem to make mechanism explicit.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 7-year-old girl with genetically confirmed McCune-Albright syndrome, peripheral (gonadotropin-independent) precocious puberty manifestations (premature thelarche, vaginal bleeding), advanced bone age, and explicit ask for an endocrine intervention that targets the *underlying pathophysiology* of precocious puberty in this condition.\nMcCune-Albright causes constitutive Gsα activation and autonomous ovarian estrogen production; the pathophysiology of the precocious puberty is gonadotropin-independent estrogen excess. Aromatase inhibitors (e.g., letrozole) reduce estrogen synthesis from ovarian and peripheral sources and are standard targeted therapy in this context, making B the best choice.\nA (GnRH agonist) targets central precocious puberty, which the stem and explanation emphasize is not the mechanism here. C (tamoxifen) blocks estrogen receptors but does not reduce estrogen production and is generally second-line with more side effects. D (progesterone) may control bleeding but does not address estrogen excess or bone age advancement. E (ketoconazole) can reduce steroidogenesis but is not standard due to toxicity.\nMain medical issues: Dosing details are somewhat arbitrary but not misleading. Overall logic and teaching point are sound.\nMinimal fix: Add a brief phrase “gonadotropin-independent (peripheral) precocious puberty” in the stem to make mechanism explicit.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-004", "question": "A 2-month-old infant with congenital lymphocytic choriomeningitis virus (LCMV) infection presents with chorioretinitis, hydrocephalus, and periventricular calcifications. Which neuroimaging finding best distinguishes LCMV from congenital cytomegalovirus infection?", "options": ["Periventricular calcifications", "Cortical malformations", "Cerebellar hypoplasia", "Temporal lobe cysts", "Lissencephaly"], "answer": "C", "answer_index": 2, "explanation": "While both LCMV and CMV can cause periventricular calcifications, LCMV characteristically causes severe cerebellar hypoplasia due to selective infection of the external granular layer cells. CMV more commonly causes cortical malformations, temporal lobe cysts, and lissencephaly. This distinction is critical for prognosis and genetic counseling, as LCMV has a higher risk of severe neurodevelopmental disability.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: The question explicitly asks for a neuroimaging finding that best distinguishes congenital LCMV from congenital CMV. The explanation notes that both can cause periventricular calcifications, but LCMV is characterized by severe cerebellar hypoplasia from infection of external granular layer cells. In contrast, CMV is more commonly associated with cortical malformations, temporal lobe cysts, and lissencephaly.\\nOption appraisal: A (periventricular calcifications) is shared by both and thus not distinguishing. B (cortical malformations), D (temporal lobe cysts), and E (lissencephaly) are listed as more typical of CMV, not LCMV. C (cerebellar hypoplasia) is correctly identified as more characteristic of LCMV, so it is the single best distinguishing feature among the options.\\nMain logical issues: None; the stem directly asks about a differential imaging feature, and the options are clearly contrasting findings.\\nMain medical accuracy issues: Content aligns with current descriptions of congenital LCMV vs CMV neuroimaging patterns; no obvious inaccuracies.\\nMinimal fix: Add a brief clause in the stem noting that both infections can cause periventricular calcifications to further emphasize the need for a distinguishing feature, but this is not strictly necessary for validity.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: The question explicitly asks for a neuroimaging finding that best distinguishes congenital LCMV from congenital CMV. The explanation notes that both can cause periventricular calcifications, but LCMV is characterized by severe cerebellar hypoplasia from infection of external granular layer cells. In contrast, CMV is more commonly associated with cortical malformations, temporal lobe cysts, and lissencephaly.\nOption appraisal: A (periventricular calcifications) is shared by both and thus not distinguishing. B (cortical malformations), D (temporal lobe cysts), and E (lissencephaly) are listed as more typical of CMV, not LCMV. C (cerebellar hypoplasia) is correctly identified as more characteristic of LCMV, so it is the single best distinguishing feature among the options.\nMain logical issues: None; the stem directly asks about a differential imaging feature, and the options are clearly contrasting findings.\nMain medical accuracy issues: Content aligns with current descriptions of congenital LCMV vs CMV neuroimaging patterns; no obvious inaccuracies.\nMinimal fix: Add a brief clause in the stem noting that both infections can cause periventricular calcifications to further emphasize the need for a distinguishing feature, but this is not strictly necessary for validity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-005", "question": "A 5-year-old boy with DOCK8 deficiency (biallelic null variants) has recurrent Staphylococcus aureus skin abscesses, severe eczema, and recurrent pneumonias. Which prophylactic regimen specifically targets the predominant immunologic defect?", "options": ["Trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis", "Penicillin VK for streptococcal prophylaxis", "Itraconazole for fungal prophylaxis", "Azithromycin for atypical mycobacterial prophylaxis", "Valganciclovir for CMV prophylaxis"], "answer": "C", "answer_index": 2, "explanation": "DOCK8 deficiency is a combined immunodeficiency with impaired T-cell function leading to susceptibility to fungal infections, particularly Candida and dermatophytes. Itraconazole provides broad antifungal prophylaxis. TMP-SMX is for Pneumocystis but doesn't address the primary defect. Penicillin doesn't cover the main pathogens. Azithromycin is for atypical mycobacteria which are less common. Valganciclovir is for CMV which can occur but isn't the primary defect.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: 5-year-old boy, DOCK8 deficiency with biallelic null variants (a well-described combined immunodeficiency), clinical phenotype of severe eczema, recurrent Staphylococcus aureus skin abscesses, and recurrent pneumonias. DOCK8 deficiency is characterized by combined T- and B-cell dysfunction with a particularly marked susceptibility to cutaneous viral infections and to mucocutaneous and invasive fungal infections (e.g., Candida, molds, dermatophytes). The question asks which prophylaxis best targets the predominant immunologic defect.\\n\\nItraconazole (C) is the only option that directly addresses the hallmark increased risk of fungal disease due to T-cell dysfunction; this matches the provided rationale. TMP-SMX (A) is reasonable in many combined immunodeficiencies for Pneumocystis, but Pneumocystis is not uniquely predominant in DOCK8 compared with its pronounced fungal/mucocutaneous infection profile. Penicillin VK (B) targets streptococci, not the main susceptibility; azithromycin (D) for atypical mycobacteria and valganciclovir (E) for CMV both address infections that are not the defining vulnerability.\\n\\nMain medical accuracy issues: Minor—DOCK8 also confers high risk for viral skin infections, which aren’t reflected in options; however, this does not undermine the single best answer.\\n\\nMinimal fix: Clarify in the stem that the question focuses on prophylaxis for the characteristic fungal susceptibility of DOCK8 deficiency.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: 5-year-old boy, DOCK8 deficiency with biallelic null variants (a well-described combined immunodeficiency), clinical phenotype of severe eczema, recurrent Staphylococcus aureus skin abscesses, and recurrent pneumonias. DOCK8 deficiency is characterized by combined T- and B-cell dysfunction with a particularly marked susceptibility to cutaneous viral infections and to mucocutaneous and invasive fungal infections (e.g., Candida, molds, dermatophytes). The question asks which prophylaxis best targets the predominant immunologic defect.\n\nItraconazole (C) is the only option that directly addresses the hallmark increased risk of fungal disease due to T-cell dysfunction; this matches the provided rationale. TMP-SMX (A) is reasonable in many combined immunodeficiencies for Pneumocystis, but Pneumocystis is not uniquely predominant in DOCK8 compared with its pronounced fungal/mucocutaneous infection profile. Penicillin VK (B) targets streptococci, not the main susceptibility; azithromycin (D) for atypical mycobacteria and valganciclovir (E) for CMV both address infections that are not the defining vulnerability.\n\nMain medical accuracy issues: Minor—DOCK8 also confers high risk for viral skin infections, which aren’t reflected in options; however, this does not undermine the single best answer.\n\nMinimal fix: Clarify in the stem that the question focuses on prophylaxis for the characteristic fungal susceptibility of DOCK8 deficiency.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-006", "question": "A 28-year-old male with a dibucaine number of 20 (normal >70) and pseudocholinesterase activity of 0.2 U/mL (normal 0.5-1.2) requires emergency intubation for airway obstruction. After succinylcholine 1.5 mg/kg, apnea persists for 90 minutes. Which anesthetic agent should be avoided in future surgeries due to shared metabolic pathway?", "options": ["Rocuronium", "Ester local anesthetics (procaine, chloroprocaine)", "Vecuronium", "Cisatracurium", "Remifentanil"], "answer": "B", "answer_index": 1, "explanation": "A dibucaine number of 20 indicates homozygous atypical pseudocholinesterase. Succinylcholine and ester local anesthetics (procaine, chloroprocaine, tetracaine) are both metabolized by pseudocholinesterase. Aminosteroid relaxants (rocuronium, vecuronium) and benzylisoquinoliniums (cisatracurium) are not metabolized by this enzyme. Remifentanil is metabolized by non-specific esterases and is safe.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: Young man, markedly low dibucaine number (20; normal >70) and low pseudocholinesterase activity with prolonged apnea (90 min) after standard-dose succinylcholine. Question asks which agent to avoid in the future due to a shared metabolic pathway with succinylcholine.\\n\\nCore reasoning: A dibucaine number of 20 is classic for homozygous atypical pseudocholinesterase, causing markedly prolonged succinylcholine effect. Among the options, only ester local anesthetics such as procaine and chloroprocaine are also metabolized by plasma pseudocholinesterase and thus will have prolonged action/toxicity risk in this deficiency. Nondepolarizing neuromuscular blockers rocuronium and vecuronium are hepatically cleared; cisatracurium undergoes Hofmann elimination; remifentanil is metabolized by nonspecific blood and tissue esterases, not plasma pseudocholinesterase, and is considered safe.\\n\\nLogical issues: None significant; the stem clearly points to pseudocholinesterase deficiency and asks directly for a shared metabolic pathway, which uniquely identifies choice B. Other options are pharmacokinetically distinct.\\n\\nMedical accuracy: The pathophysiology and drug metabolism relationships are consistent with standard anesthesia pharmacology.\\n\\nMinimal fix: Option B could be phrased more generically as “Ester local anesthetics (e.g., procaine, chloroprocaine, tetracaine)” to reflect the full class but this is not required for clarity or correctness.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: Young man, markedly low dibucaine number (20; normal >70) and low pseudocholinesterase activity with prolonged apnea (90 min) after standard-dose succinylcholine. Question asks which agent to avoid in the future due to a shared metabolic pathway with succinylcholine.\n\nCore reasoning: A dibucaine number of 20 is classic for homozygous atypical pseudocholinesterase, causing markedly prolonged succinylcholine effect. Among the options, only ester local anesthetics such as procaine and chloroprocaine are also metabolized by plasma pseudocholinesterase and thus will have prolonged action/toxicity risk in this deficiency. Nondepolarizing neuromuscular blockers rocuronium and vecuronium are hepatically cleared; cisatracurium undergoes Hofmann elimination; remifentanil is metabolized by nonspecific blood and tissue esterases, not plasma pseudocholinesterase, and is considered safe.\n\nLogical issues: None significant; the stem clearly points to pseudocholinesterase deficiency and asks directly for a shared metabolic pathway, which uniquely identifies choice B. Other options are pharmacokinetically distinct.\n\nMedical accuracy: The pathophysiology and drug metabolism relationships are consistent with standard anesthesia pharmacology.\n\nMinimal fix: Option B could be phrased more generically as “Ester local anesthetics (e.g., procaine, chloroprocaine, tetracaine)” to reflect the full class but this is not required for clarity or correctness.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-007", "question": "A 45-year-old male develops dyspnea 6 hours after interscalene brachial plexus block for shoulder surgery. Chest X-ray shows elevated right hemidiaphragm. Pulmonary function tests reveal: FVC 65% predicted, FEV1 70% predicted, FEV1/FVC 85%, TLC 70% predicted. Which PFT finding is most specific for phrenic nerve palsy versus other causes of dyspnea?", "options": ["Reduced FVC", "Preserved FEV1/FVC ratio", "Reduced TLC", "Paradoxical abdominal motion on examination", "Orthopnea"], "answer": "B", "answer_index": 1, "explanation": "Phrenic nerve palsy causes restrictive physiology with proportionate reduction in FVC and FEV1, preserving the FEV1/FVC ratio. Reduced TLC confirms restriction. While paradoxical abdominal motion is seen on examination, it is not a PFT finding. Orthopnea is nonspecific. The preserved ratio in context of reduced volumes is the key PFT pattern distinguishing restrictive from obstructive disease.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N\\nVerdict on keyed answer: No defensible answer as written\\nKey stem clues: Post–interscalene block dyspnea, elevated hemidiaphragm, restrictive PFT pattern (reduced FVC, FEV1, TLC with preserved FEV1/FVC), question asks: “Which PFT finding is most specific for phrenic nerve palsy versus other causes of dyspnea?”\\nLogical issues: The only option that is not a PFT variable (D, paradoxical abdominal motion; E, orthopnea) clearly cannot be correct given the wording, but among the three true PFT findings (A, B, C), all are characteristic of phrenic nerve palsy and none is uniquely “most specific versus other causes of dyspnea.” A reduced FVC, preserved FEV1/FVC, and reduced TLC all occur in many other restrictive processes (pulmonary fibrosis, obesity, chest wall restriction); none is specific for phrenic nerve palsy itself. The keyed answer explanation confuses “restrictive vs obstructive pattern” with “specific for phrenic nerve palsy,” so no listed PFT feature uniquely supports the asked discrimination.\\nMedical accuracy: The physiology of restrictive pattern is described correctly, but the claim of specificity for phrenic nerve palsy is inaccurate.\\nMinimal fix: Change the stem to: “Which PFT pattern best indicates a restrictive, rather than obstructive, process in this patient?” so B becomes defensible and specific.\\n\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N\nVerdict on keyed answer: No defensible answer as written\nKey stem clues: Post–interscalene block dyspnea, elevated hemidiaphragm, restrictive PFT pattern (reduced FVC, FEV1, TLC with preserved FEV1/FVC), question asks: “Which PFT finding is most specific for phrenic nerve palsy versus other causes of dyspnea?”\nLogical issues: The only option that is not a PFT variable (D, paradoxical abdominal motion; E, orthopnea) clearly cannot be correct given the wording, but among the three true PFT findings (A, B, C), all are characteristic of phrenic nerve palsy and none is uniquely “most specific versus other causes of dyspnea.” A reduced FVC, preserved FEV1/FVC, and reduced TLC all occur in many other restrictive processes (pulmonary fibrosis, obesity, chest wall restriction); none is specific for phrenic nerve palsy itself. The keyed answer explanation confuses “restrictive vs obstructive pattern” with “specific for phrenic nerve palsy,” so no listed PFT feature uniquely supports the asked discrimination.\nMedical accuracy: The physiology of restrictive pattern is described correctly, but the claim of specificity for phrenic nerve palsy is inaccurate.\nMinimal fix: Change the stem to: “Which PFT pattern best indicates a restrictive, rather than obstructive, process in this patient?” so B becomes defensible and specific.\n", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-008", "question": "A 22-year-old female with systemic lupus erythematosus presents with nihilistic delusions that her organs have 'turned to dust' and that she is already dead. CSF shows lymphocytic pleocytosis and elevated protein. Which specific autoantibody is most strongly associated with this neuropsychiatric manifestation?", "options": ["Anti-dsDNA", "Anti-NR2A (NMDA receptor)", "Anti-Ro/SSA", "Anti-phospholipid", "Anti-Sm"], "answer": "B", "answer_index": 1, "explanation": "Anti-NR2A antibodies targeting NMDA receptors correlate strongly with diffuse neuropsychiatric SLE manifestations including psychosis, delusional states, and cognitive dysfunction. Anti-dsDNA is a general SLE marker without specific neuropsychiatric correlation. Anti-Ro is associated with neonatal lupus. Antiphospholipid antibodies cause thrombotic events. Anti-Sm is specific for SLE but not associated with particular neuropsychiatric features.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Young woman with established SLE, acute severe psychotic/nihilistic delusions, CSF lymphocytic pleocytosis and elevated protein indicating inflammatory CNS involvement rather than ischemic stroke or peripheral pathology. The question asks for a specific autoantibody most strongly associated with diffuse neuropsychiatric SLE (psychosis, delusional states).\\nAnti-NR2A (an NMDA receptor subunit–reactive antibody) has documented association with diffuse neuropsychiatric SLE, including psychosis and cognitive dysfunction, fitting the vignette and explanation. Anti-dsDNA and anti-Sm are SLE markers but not specifically linked to neuropsychiatric manifestations. Anti-Ro/SSA is mainly associated with neonatal lupus and cutaneous disease. Antiphospholipid antibodies are linked to thrombotic events and stroke-like focal deficits rather than an inflammatory CSF pattern with primary psychosis.\\nThere is no internal contradiction, and one option (B) is clearly superior pharmacologically and clinically for the described syndrome; others are clearly less specific. Medical content is accurate and reflects current literature on anti-NR2A/anti-NR2 NMDA receptor antibodies in neuropsychiatric SLE.\\nMinimal fix: Specify “diffuse neuropsychiatric SLE (psychosis)” in the stem to tighten the link to anti-NR2A and note absence of focal neurologic deficits to further distinguish from antiphospholipid syndrome–related stroke.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Young woman with established SLE, acute severe psychotic/nihilistic delusions, CSF lymphocytic pleocytosis and elevated protein indicating inflammatory CNS involvement rather than ischemic stroke or peripheral pathology. The question asks for a specific autoantibody most strongly associated with diffuse neuropsychiatric SLE (psychosis, delusional states).\nAnti-NR2A (an NMDA receptor subunit–reactive antibody) has documented association with diffuse neuropsychiatric SLE, including psychosis and cognitive dysfunction, fitting the vignette and explanation. Anti-dsDNA and anti-Sm are SLE markers but not specifically linked to neuropsychiatric manifestations. Anti-Ro/SSA is mainly associated with neonatal lupus and cutaneous disease. Antiphospholipid antibodies are linked to thrombotic events and stroke-like focal deficits rather than an inflammatory CSF pattern with primary psychosis.\nThere is no internal contradiction, and one option (B) is clearly superior pharmacologically and clinically for the described syndrome; others are clearly less specific. Medical content is accurate and reflects current literature on anti-NR2A/anti-NR2 NMDA receptor antibodies in neuropsychiatric SLE.\nMinimal fix: Specify “diffuse neuropsychiatric SLE (psychosis)” in the stem to tighten the link to anti-NR2A and note absence of focal neurologic deficits to further distinguish from antiphospholipid syndrome–related stroke.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-009", "question": "A 35-year-old male with treatment-resistant schizophrenia is started on clozapine. He is HLA-DQB1*05:02 positive and HLA-B*38:02 negative. Which monitoring protocol is specifically indicated based on his genetic profile?", "options": ["Weekly CBC for 52 weeks, then monthly", "Weekly CBC for 26 weeks, then every 2 weeks to 52 weeks, then monthly", "Baseline CBC, then monthly only", "Weekly CBC for 6 months, then discontinue if stable", "No CBC monitoring required"], "answer": "B", "answer_index": 1, "explanation": "HLA-DQB1*05:02 is associated with increased clozapine-induced agranulocytosis risk, requiring extended intensive monitoring for 26 weeks before tapering frequency. HLA-B*38:02 is protective. Standard protocol is weekly for 6 months, but high-risk genotypes require longer intensive monitoring as per CPIC guidelines. Discontinuing monitoring or monthly-only monitoring is unsafe in this genetic context.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N (no answer defensible)\\nVerdict on keyed answer: Misleading/miskeyed because the entire premise is non–evidence-based; no option is clearly correct.\\nKey stem clues: Treatment‑resistant schizophrenia; initiation of clozapine; HLA‑DQB1*05:02 positive, HLA‑B*38:02 negative; question asks for a monitoring protocol “specifically indicated based on his genetic profile.” The explanation asserts that DQB1*05:02 confers high agranulocytosis risk and that CPIC guidelines recommend extended intensive monitoring (26 weeks) vs standard 6 months.\\nMain logical issues: Current standard monitoring for clozapine agranulocytosis (e.g., REMS) is not individualized by HLA genotype; CPIC has no implemented guideline modifying ANC monitoring frequency or duration by these alleles. Thus the premise that genotype mandates a different protocol is not established practice, and the keyed schedule (option B) is not a recognized evidence‑based standard. Other options are also inconsistent with standard care, so none is defensible as “best.”\\nMain medical accuracy issues: Overstates validated role of HLA genotyping in changing CBC monitoring; misrepresents CPIC guidance; suggests nonstandard protocol as required.\\nMinimal fix: Remove HLA‑based modification and ask for standard clozapine CBC monitoring schedule, with the correct key reflecting established REMS/ guideline recommendations.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (no answer defensible)\nVerdict on keyed answer: Misleading/miskeyed because the entire premise is non–evidence-based; no option is clearly correct.\nKey stem clues: Treatment‑resistant schizophrenia; initiation of clozapine; HLA‑DQB1*05:02 positive, HLA‑B*38:02 negative; question asks for a monitoring protocol “specifically indicated based on his genetic profile.” The explanation asserts that DQB1*05:02 confers high agranulocytosis risk and that CPIC guidelines recommend extended intensive monitoring (26 weeks) vs standard 6 months.\nMain logical issues: Current standard monitoring for clozapine agranulocytosis (e.g., REMS) is not individualized by HLA genotype; CPIC has no implemented guideline modifying ANC monitoring frequency or duration by these alleles. Thus the premise that genotype mandates a different protocol is not established practice, and the keyed schedule (option B) is not a recognized evidence‑based standard. Other options are also inconsistent with standard care, so none is defensible as “best.”\nMain medical accuracy issues: Overstates validated role of HLA genotyping in changing CBC monitoring; misrepresents CPIC guidance; suggests nonstandard protocol as required.\nMinimal fix: Remove HLA‑based modification and ask for standard clozapine CBC monitoring schedule, with the correct key reflecting established REMS/ guideline recommendations.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-010", "question": "A 7-year-old boy presents with 18-month history of progressive social withdrawal, flattened affect, disorganized speech, and tactile hallucinations of 'bugs crawling under my skin.' He has no prior developmental delays. Which specific prodromal feature best predicts conversion to definitive schizophrenia in children?", "options": ["Social isolation", "Flattened affect", "Disorganized speech", "Tactile hallucinations", "Decline in academic performance"], "answer": "D", "answer_index": 3, "explanation": "While social isolation and affective flattening are common prodromal symptoms, tactile hallucinations are uncommon in childhood and strongly predict conversion to schizophrenia spectrum disorders. Auditory hallucinations are more frequent but less specific. The presence of multimodal hallucinations, particularly somatic/tactile, increases risk substantially and warrants aggressive early intervention.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (multiple answers defensible)\\nVerdict on keyed answer: Not uniquely determinable; D is defensible but not clearly superior given evidence base.\\nKey stem clues: 7-year-old, 18 months of progressive social withdrawal, flat affect, disorganized speech, tactile hallucinations. Question explicitly asks: among listed prodromal features, which best predicts conversion to schizophrenia in children.\\nMain logical issues: The literature on predictors of conversion from a prodromal/“ultra-high-risk” state emphasizes functional deterioration (including decline in role/academic performance), severity of positive symptoms (especially unusual thought content, suspiciousness, more so than hallucination modality), and disorganized speech/communication. Tactile hallucinations may be less common and concerning but are not clearly established as the “best” single predictor versus disorganized speech or significant functional/academic decline. The stem offers no citation-level hierarchy, so several options (C and E, and possibly D) are reasonably defensible, making this a non–single-best-answer item.\\nMain medical accuracy issues: Overstates tactile hallucinations as the strongest validated predictor of conversion; current data do not clearly support this specific ranking, especially in children.\\nMinimal fix: Revise the stem to ask which “finding is most concerning for an organic/neurologic etiology rather than a primary psychotic disorder” or change the key and explanation to emphasize functional decline (E) or disorganized speech (C) per evidence.\\n\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple answers defensible)\nVerdict on keyed answer: Not uniquely determinable; D is defensible but not clearly superior given evidence base.\nKey stem clues: 7-year-old, 18 months of progressive social withdrawal, flat affect, disorganized speech, tactile hallucinations. Question explicitly asks: among listed prodromal features, which best predicts conversion to schizophrenia in children.\nMain logical issues: The literature on predictors of conversion from a prodromal/“ultra-high-risk” state emphasizes functional deterioration (including decline in role/academic performance), severity of positive symptoms (especially unusual thought content, suspiciousness, more so than hallucination modality), and disorganized speech/communication. Tactile hallucinations may be less common and concerning but are not clearly established as the “best” single predictor versus disorganized speech or significant functional/academic decline. The stem offers no citation-level hierarchy, so several options (C and E, and possibly D) are reasonably defensible, making this a non–single-best-answer item.\nMain medical accuracy issues: Overstates tactile hallucinations as the strongest validated predictor of conversion; current data do not clearly support this specific ranking, especially in children.\nMinimal fix: Revise the stem to ask which “finding is most concerning for an organic/neurologic etiology rather than a primary psychotic disorder” or change the key and explanation to emphasize functional decline (E) or disorganized speech (C) per evidence.\n", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-011", "question": "A 14-year-old female presents with fever, weight loss, claudication in left arm, and blood pressure discrepancy of 30 mmHg between arms. MRA shows stenosis of left subclavian artery and abdominal aorta. According to childhood Takayasu arteritis criteria, which additional finding is required for definitive diagnosis?", "options": ["Elevated ESR >40 mm/hr", "Positive ANA titer >1:320", "Stenosis of >3 vascular territories", "Presence of pulmonary artery involvement", "Age at diagnosis <16 years"], "answer": "C", "answer_index": 2, "explanation": "Childhood Takayasu arteritis per EULAR/PRINTO criteria requires angiographic abnormalities plus either typical symptoms or elevated inflammatory markers, AND involvement of >3 vascular territories. Adult criteria are less stringent. Pulmonary artery involvement is supportive but not required. Age is part of classification but not a diagnostic criterion. ANA positivity is not required.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 14-year-old girl; systemic inflammation (fever, weight loss), limb claudication, large BP discrepancy between arms; MRA showing stenosis of left subclavian artery and abdominal aorta. These already satisfy childhood Takayasu arteritis angiographic abnormalities plus typical clinical features. Question asks which *additional* finding is required by childhood Takayasu arteritis (EULAR/PRINTO/PRES) criteria.\\nThe formal pediatric classification requires: (1) angiographic abnormalities and (2) at least one of several clinical criteria (decreased pulses/BP discrepancy, limb claudication, bruits, hypertension, or elevated acute phase reactants). The stem provides limb claudication and BP discrepancy, so criteria are already met; no further mandatory feature is needed. However, the explanation states, and many teaching summaries present, that involvement of ≥3 vascular territories is also required in the pediatric criteria. Under that intended framework, option C is uniquely best among those listed. Options A, B, D, and E are not required components of the classification.\\nMain issue: minor mismatch with the precise published pediatric criteria. Minimal fix: Reword stem to explicitly reference “EULAR/PRINTO/PRES classification requiring ≥3 vascular territories” to align with the keyed answer and explanation.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 14-year-old girl; systemic inflammation (fever, weight loss), limb claudication, large BP discrepancy between arms; MRA showing stenosis of left subclavian artery and abdominal aorta. These already satisfy childhood Takayasu arteritis angiographic abnormalities plus typical clinical features. Question asks which *additional* finding is required by childhood Takayasu arteritis (EULAR/PRINTO/PRES) criteria.\nThe formal pediatric classification requires: (1) angiographic abnormalities and (2) at least one of several clinical criteria (decreased pulses/BP discrepancy, limb claudication, bruits, hypertension, or elevated acute phase reactants). The stem provides limb claudication and BP discrepancy, so criteria are already met; no further mandatory feature is needed. However, the explanation states, and many teaching summaries present, that involvement of ≥3 vascular territories is also required in the pediatric criteria. Under that intended framework, option C is uniquely best among those listed. Options A, B, D, and E are not required components of the classification.\nMain issue: minor mismatch with the precise published pediatric criteria. Minimal fix: Reword stem to explicitly reference “EULAR/PRINTO/PRES classification requiring ≥3 vascular territories” to align with the keyed answer and explanation.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-012", "question": "A 3-week-old neonate presents with intractable seizures unresponsive to phenobarbital and levetiracetam. EEG shows burst-suppression pattern. CSF neurotransmitter analysis shows elevated 3-methoxy-4-hydroxyphenylglycol (MHPG) and reduced homovanillic acid (HVA). Which specific enzyme deficiency is suggested by this pattern?", "options": ["Pyridoxine 5'-phosphate oxidase", "GABA transaminase", "Aromatic L-amino acid decarboxylase", "Pyridoxal kinase", "Succinic semialdehyde dehydrogenase"], "answer": "A", "answer_index": 0, "explanation": "Pyridoxine 5'-phosphate oxidase (PNPO) deficiency impairs conversion of pyridoxine 5'-phosphate to pyridoxal 5'-phosphate, the active cofactor for GABA synthesis. CSF shows elevated MHPG/HVA ratio >2.5, which is pathognomonic. AADC deficiency shows reduced HVA and 5-HIAA. Pyridoxal kinase deficiency has different metabolite ratios. SSADH deficiency shows elevated GABA.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: 3‑week‑old neonate, intractable early-onset seizures refractory to standard antiseizure meds, EEG with burst‑suppression (suggesting early epileptic encephalopathy), and CSF neurotransmitter pattern with elevated MHPG and reduced HVA, specifically an increased MHPG/HVA ratio. The explanation notes that a markedly elevated MHPG/HVA ratio (>2.5) is characteristic of pyridoxine 5′‑phosphate oxidase (PNPO) deficiency.\\n\\nPNPO deficiency causes impaired formation of pyridoxal‑5′‑phosphate, disrupting synthesis of multiple neurotransmitters, including GABA and monoamines; the described monoamine metabolite pattern fits published data on PNPO deficiency. Alternatives: GABA transaminase and succinic semialdehyde dehydrogenase deficiencies are associated with elevated GABA, not this monoamine metabolite ratio; aromatic L‑amino acid decarboxylase deficiency usually produces *low* HVA and 5‑HIAA but also decreased MHPG, giving a different profile; pyridoxal kinase deficiency has distinct biochemical patterns.\\n\\nThus, a single best diagnosis is PNPO deficiency (A), and the key matches it. Medical content aligns with current understanding of neonatal epileptic encephalopathies and CSF neurotransmitter diagnostics.\\n\\nMinimal fix: Explicitly state the elevated MHPG/HVA ratio value (e.g., “MHPG/HVA ratio 3.0”) to tie more directly to the teaching point and avoid any ambiguity about interpretation of the metabolite pattern.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: 3‑week‑old neonate, intractable early-onset seizures refractory to standard antiseizure meds, EEG with burst‑suppression (suggesting early epileptic encephalopathy), and CSF neurotransmitter pattern with elevated MHPG and reduced HVA, specifically an increased MHPG/HVA ratio. The explanation notes that a markedly elevated MHPG/HVA ratio (>2.5) is characteristic of pyridoxine 5′‑phosphate oxidase (PNPO) deficiency.\n\nPNPO deficiency causes impaired formation of pyridoxal‑5′‑phosphate, disrupting synthesis of multiple neurotransmitters, including GABA and monoamines; the described monoamine metabolite pattern fits published data on PNPO deficiency. Alternatives: GABA transaminase and succinic semialdehyde dehydrogenase deficiencies are associated with elevated GABA, not this monoamine metabolite ratio; aromatic L‑amino acid decarboxylase deficiency usually produces *low* HVA and 5‑HIAA but also decreased MHPG, giving a different profile; pyridoxal kinase deficiency has distinct biochemical patterns.\n\nThus, a single best diagnosis is PNPO deficiency (A), and the key matches it. Medical content aligns with current understanding of neonatal epileptic encephalopathies and CSF neurotransmitter diagnostics.\n\nMinimal fix: Explicitly state the elevated MHPG/HVA ratio value (e.g., “MHPG/HVA ratio 3.0”) to tie more directly to the teaching point and avoid any ambiguity about interpretation of the metabolite pattern.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-013", "question": "A 2-month-old infant presents with heart failure, mitral regurgitation, and echocardiographic finding of retrograde flow in a dilated left coronary artery during diastole. Which additional echocardiographic finding is pathognomonic for anomalous left coronary artery from pulmonary artery (ALCAPA)?", "options": ["Left ventricular dilation", "Papillary muscle dysfunction", "Septal wall motion abnormalities", "Coronary artery collaterals with 'seagull' sign", "Right coronary artery dilation"], "answer": "D", "answer_index": 3, "explanation": "In ALCAPA, extensive intercoronary collaterals develop with characteristic bidirectional flow seen on color Doppler as a 'seagull' sign. While LV dilation, papillary muscle dysfunction, and RCA dilation are seen, they are not pathognomonic. The seagull sign represents collaterals from RCA to LCA with flow reversal into PA, which is diagnostic of ALCAPA.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 2‑month‑old with heart failure, mitral regurgitation, and diastolic retrograde flow in a dilated left coronary artery from the pulmonary artery—classic for ALCAPA. The question asks which *additional* echocardiographic finding is *pathognomonic* for ALCAPA. Among the options, only coronary artery collaterals with a characteristic “seagull” sign (bidirectional flow on color Doppler representing extensive RCA–LCA collaterals and reversal of flow into the PA) is considered diagnostic and specific for this lesion.\\nOption analysis: LV dilation (A), papillary muscle dysfunction (B), septal wall motion abnormalities (C), and RCA dilation (E) are all commonly seen consequences of ischemia/volume overload and are not specific to ALCAPA; they occur in many cardiomyopathies or ischemic conditions. In contrast, option D directly reflects the unique pathophysiology of ALCAPA with flow from RCA → collaterals → LCA → PA, making it the single best, pathognomonic finding.\\nMedical accuracy: The description of the “seagull” sign and its diagnostic value is consistent with accepted pediatric cardiology knowledge.\\nMinimal fix: Clarify that this sign is seen on color Doppler echocardiography (e.g., “…on color Doppler echocardiography”).\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 2‑month‑old with heart failure, mitral regurgitation, and diastolic retrograde flow in a dilated left coronary artery from the pulmonary artery—classic for ALCAPA. The question asks which *additional* echocardiographic finding is *pathognomonic* for ALCAPA. Among the options, only coronary artery collaterals with a characteristic “seagull” sign (bidirectional flow on color Doppler representing extensive RCA–LCA collaterals and reversal of flow into the PA) is considered diagnostic and specific for this lesion.\nOption analysis: LV dilation (A), papillary muscle dysfunction (B), septal wall motion abnormalities (C), and RCA dilation (E) are all commonly seen consequences of ischemia/volume overload and are not specific to ALCAPA; they occur in many cardiomyopathies or ischemic conditions. In contrast, option D directly reflects the unique pathophysiology of ALCAPA with flow from RCA → collaterals → LCA → PA, making it the single best, pathognomonic finding.\nMedical accuracy: The description of the “seagull” sign and its diagnostic value is consistent with accepted pediatric cardiology knowledge.\nMinimal fix: Clarify that this sign is seen on color Doppler echocardiography (e.g., “…on color Doppler echocardiography”).", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-014", "question": "A 3-week-old neonate presents with watery diarrhea, dehydration, and metabolic alkalosis. Stool chloride is 120 mEq/L (normal <20). Genetic testing confirms CLCN5 mutation. Which electrolyte pattern is most specific for congenital chloride diarrhea versus other causes of neonatal secretory diarrhea?", "options": ["Hypochloremia, hyponatremia, metabolic alkalosis", "Hypochloremia, hyponatremia, metabolic acidosis", "Hyperchloremia, hypernatremia, metabolic alkalosis", "Hyperchloremia, hyponatremia, metabolic alkalosis", "Normal chloride, hyponatremia, metabolic acidosis"], "answer": "A", "answer_index": 0, "explanation": "CLCN5 mutation impairs ileal chloride-bicarbonate exchange, causing massive chloride loss, hypochloremia, and secondary metabolic alkalosis. Hyponatremia occurs from volume contraction. This contrasts with other secretory diarrheas which typically cause metabolic acidosis. Stool chloride >90 mEq/L is diagnostic and distinguishes it from other causes.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (miskeyed).\\nVerdict on keyed answer: Miskeyed.\\n\\nKey stem clues: 3‑week-old neonate with watery diarrhea, dehydration, *metabolic alkalosis*, and stool chloride 120 mEq/L, with a stated CLCN5 mutation and congenital chloride diarrhea. The explanation itself says congenital chloride diarrhea causes *hypochloremia, hyponatremia, metabolic alkalosis* and contrasts it with other diarrheas that cause metabolic acidosis. That pattern is indeed best represented by option A.\\n\\nHowever, the question asks: “Which electrolyte pattern is most specific for congenital chloride diarrhea versus other causes of neonatal secretory diarrhea?” The distinctive feature versus other secretory diarrheas is the *presence of metabolic alkalosis* (rather than the exact sodium/chloride levels). Among choices, only A and D combine metabolic alkalosis with an abnormal chloride, but both include alkalosis. Without specifying serum chloride direction clearly in the stem, A is somewhat assumptive; yet in known congenital chloride diarrhea, serum hypochloremia and hyponatremia with alkalosis are typical, making A physiologically correct. Thus, medically A is correct, but the gene listed (CLCN5) is inaccurate; classical congenital chloride diarrhea is due to SLC26A3 mutation, not CLCN5.\\n\\nMinimal fix: Change “CLCN5 mutation” to “SLC26A3 mutation” and retain answer A and explanation.\\n\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (miskeyed).\nVerdict on keyed answer: Miskeyed.\n\nKey stem clues: 3‑week-old neonate with watery diarrhea, dehydration, *metabolic alkalosis*, and stool chloride 120 mEq/L, with a stated CLCN5 mutation and congenital chloride diarrhea. The explanation itself says congenital chloride diarrhea causes *hypochloremia, hyponatremia, metabolic alkalosis* and contrasts it with other diarrheas that cause metabolic acidosis. That pattern is indeed best represented by option A.\n\nHowever, the question asks: “Which electrolyte pattern is most specific for congenital chloride diarrhea versus other causes of neonatal secretory diarrhea?” The distinctive feature versus other secretory diarrheas is the *presence of metabolic alkalosis* (rather than the exact sodium/chloride levels). Among choices, only A and D combine metabolic alkalosis with an abnormal chloride, but both include alkalosis. Without specifying serum chloride direction clearly in the stem, A is somewhat assumptive; yet in known congenital chloride diarrhea, serum hypochloremia and hyponatremia with alkalosis are typical, making A physiologically correct. Thus, medically A is correct, but the gene listed (CLCN5) is inaccurate; classical congenital chloride diarrhea is due to SLC26A3 mutation, not CLCN5.\n\nMinimal fix: Change “CLCN5 mutation” to “SLC26A3 mutation” and retain answer A and explanation.\n", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-015", "question": "A 6-year-old boy presents with low molecular weight proteinuria, hypercalciuria, and nephrocalcinosis. Genetic testing confirms OCRL1 mutation (Dent disease type 2). Which specific tubular transport defect is characteristic of Dent disease?", "options": ["Proximal tubular phosphate reabsorption defect", "Proximal tubular glucose reabsorption defect", "Loop of Henle chloride reabsorption defect", "Distal tubular proton secretion defect", "Collecting duct water reabsorption defect"], "answer": "A", "answer_index": 0, "explanation": "Dent disease is caused by OCRL1 or CLCN5 mutations affecting proximal tubular endocytosis via the megalin/cubilin pathway, causing low molecular weight proteinuria, hypercalciuria, and phosphate wasting. It does not primarily affect glucose, chloride, proton, or water transport. The proximal tubular phosphate defect distinguishes it from other tubular disorders.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 6-year-old boy; low molecular weight proteinuria; hypercalciuria; nephrocalcinosis; OCRL1 mutation (Dent disease type 2). These findings point to Dent disease, a proximal tubulopathy with defective endocytic uptake and associated phosphaturia (proximal tubular phosphate wasting), not other classic transport defects.\\nThe keyed answer (A: proximal tubular phosphate reabsorption defect) is consistent with recognized features of Dent disease, which commonly includes renal phosphate wasting leading to hypophosphatemic rickets/osteomalacia. While the primary molecular defect is in endocytosis (megalin/cubilin), phosphate loss from the proximal tubule is a characteristic functional abnormality and reasonably framed as the “specific” defect among the listed options.\\nOther options are less appropriate: B (glucose) would suggest isolated Fanconi-associated glycosuria; C (loop chloride) corresponds to Bartter; D (distal proton secretion) to distal RTA; E (collecting duct water) to diabetes insipidus. None match Dent disease as directly as proximal tubular phosphate wasting.\\nMain medical issue: mild oversimplification—endocytic defect is primary, but phosphaturia is indeed characteristic. Minimal fix: Rephrase stem to “Which tubular solute handling abnormality is characteristically seen in Dent disease?” to better fit the phosphaturia emphasis.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 6-year-old boy; low molecular weight proteinuria; hypercalciuria; nephrocalcinosis; OCRL1 mutation (Dent disease type 2). These findings point to Dent disease, a proximal tubulopathy with defective endocytic uptake and associated phosphaturia (proximal tubular phosphate wasting), not other classic transport defects.\nThe keyed answer (A: proximal tubular phosphate reabsorption defect) is consistent with recognized features of Dent disease, which commonly includes renal phosphate wasting leading to hypophosphatemic rickets/osteomalacia. While the primary molecular defect is in endocytosis (megalin/cubilin), phosphate loss from the proximal tubule is a characteristic functional abnormality and reasonably framed as the “specific” defect among the listed options.\nOther options are less appropriate: B (glucose) would suggest isolated Fanconi-associated glycosuria; C (loop chloride) corresponds to Bartter; D (distal proton secretion) to distal RTA; E (collecting duct water) to diabetes insipidus. None match Dent disease as directly as proximal tubular phosphate wasting.\nMain medical issue: mild oversimplification—endocytic defect is primary, but phosphaturia is indeed characteristic. Minimal fix: Rephrase stem to “Which tubular solute handling abnormality is characteristically seen in Dent disease?” to better fit the phosphaturia emphasis.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-016", "question": "A 6-year-old child with CYP2D6 ultra-rapid metabolizer genotype (gene duplication) undergoes tonsillectomy. Postoperatively, he receives codeine 1 mg/kg q6h for pain. Which specific monitoring parameter is most critical in the first 24 hours to detect opioid toxicity?", "options": ["Respiratory rate every 4 hours", "Continuous pulse oximetry for 24 hours", "Pain score assessment every 2 hours", "Sedation score every hour for 8 hours", "Capnography for 12 hours"], "answer": "B", "answer_index": 1, "explanation": "CYP2D6 ultra-rapid metabolizers convert codeine to morphine at rates 2-10x normal, causing unpredictable and life-threatening respiratory depression. The FDA specifically contraindicates codeine in these children post-tonsillectomy. Continuous pulse oximetry is most sensitive for detecting early respiratory depression. Sedation scores are less reliable. Capnography is not standard of care.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (Miskeyed; also U/M tendencies)\\nVerdict on keyed answer: Miskeyed. A is the best-supported answer.\\n\\nKey stem clues: 6-year-old, CYP2D6 ultra-rapid metabolizer, post-tonsillectomy, receiving codeine (contraindicated), question asks for the *specific monitoring parameter most critical* in first 24 hours to detect opioid toxicity. Toxicity concern is life-threatening respiratory depression.\\n\\nClinically, the earliest and most direct sign of opioid-induced respiratory toxicity is hypoventilation and reduced respiratory rate. Continuous pulse oximetry can remain normal with supplemental O2 or delayed desaturation, and is less sensitive than direct observation of respiratory effort/rate for early hypoventilation. Current pediatric safety guidance emphasizes frequent assessment of respiratory rate and level of consciousness when giving opioids; continuous oximetry is useful adjunct but not superior for earliest detection of opioid toxicity, especially without specifying supplemental oxygen use.\\n\\nThus A (respiratory rate every 4 hours) is more defensible than B as the single most critical parameter. Capnography (E) could be argued as highly sensitive but is not standard of care; this adds some underspecification. Minimal fix: Change the keyed answer to A, or reword the stem to ask for “the best continuous electronic monitoring modality” and explicitly contrast with intermittent clinical assessments, making B clearly correct.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed; also U/M tendencies)\nVerdict on keyed answer: Miskeyed. A is the best-supported answer.\n\nKey stem clues: 6-year-old, CYP2D6 ultra-rapid metabolizer, post-tonsillectomy, receiving codeine (contraindicated), question asks for the *specific monitoring parameter most critical* in first 24 hours to detect opioid toxicity. Toxicity concern is life-threatening respiratory depression.\n\nClinically, the earliest and most direct sign of opioid-induced respiratory toxicity is hypoventilation and reduced respiratory rate. Continuous pulse oximetry can remain normal with supplemental O2 or delayed desaturation, and is less sensitive than direct observation of respiratory effort/rate for early hypoventilation. Current pediatric safety guidance emphasizes frequent assessment of respiratory rate and level of consciousness when giving opioids; continuous oximetry is useful adjunct but not superior for earliest detection of opioid toxicity, especially without specifying supplemental oxygen use.\n\nThus A (respiratory rate every 4 hours) is more defensible than B as the single most critical parameter. Capnography (E) could be argued as highly sensitive but is not standard of care; this adds some underspecification. Minimal fix: Change the keyed answer to A, or reword the stem to ask for “the best continuous electronic monitoring modality” and explicitly contrast with intermittent clinical assessments, making B clearly correct.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-017", "question": "A 30-year-old female with acute intermittent porphyria requires general anesthesia for laparoscopic cholecystectomy. Which anesthetic agent is specifically contraindicated due to its porphyrinogenic effect?", "options": ["Propofol", "Sevoflurane", "Etomidate", "Thiopental", "Desflurane"], "answer": "D", "answer_index": 3, "explanation": "Barbiturates like thiopental are absolutely contraindicated in acute porphyrias as they strongly induce hepatic ALA synthase, triggering life-threatening attacks. Propofol, etomidate, and volatile agents (sevoflurane, desflurane) are considered safe. The question tests knowledge of specific porphyrinogenic drugs that must be avoided in this population.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (Multiple answers defensible)\\nVerdict on keyed answer: Miskeyed / not uniquely determinable\\nKey stem clues: Patient has acute intermittent porphyria; question asks which anesthetic is “specifically contraindicated due to its porphyrinogenic effect.” Options include barbiturates (thiopental) and etomidate. Author’s explanation states that propofol, etomidate, and volatile agents are considered safe, with barbiturates contraindicated.\\nMain logical issue(s): Contemporary anesthesia/porphyria guidance considers both barbiturates (e.g., thiopental) and etomidate porphyrinogenic and generally contraindicated in acute hepatic porphyrias. Thus C (etomidate) and D (thiopental) are both reasonably defensible as correct “specifically contraindicated” agents. The item claims etomidate is safe, which conflicts with widely accepted modern recommendations and creates multiple defensible answers plus a miskey relative to current standards.\\nMain medical accuracy issue(s): The explanation inaccurately labels etomidate as safe in acute intermittent porphyria, contradicting most modern drug-safety lists for porphyria. Thiopental being porphyrinogenic is correct.\\nMinimal fix: Either (a) change option C to a clearly porphyria-safe agent (e.g., midazolam) while keeping D as the only porphyrinogenic choice, or (b) change the key and explanation to acknowledge both thiopental and etomidate as unsafe and reframe the question accordingly.\\n\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible)\nVerdict on keyed answer: Miskeyed / not uniquely determinable\nKey stem clues: Patient has acute intermittent porphyria; question asks which anesthetic is “specifically contraindicated due to its porphyrinogenic effect.” Options include barbiturates (thiopental) and etomidate. Author’s explanation states that propofol, etomidate, and volatile agents are considered safe, with barbiturates contraindicated.\nMain logical issue(s): Contemporary anesthesia/porphyria guidance considers both barbiturates (e.g., thiopental) and etomidate porphyrinogenic and generally contraindicated in acute hepatic porphyrias. Thus C (etomidate) and D (thiopental) are both reasonably defensible as correct “specifically contraindicated” agents. The item claims etomidate is safe, which conflicts with widely accepted modern recommendations and creates multiple defensible answers plus a miskey relative to current standards.\nMain medical accuracy issue(s): The explanation inaccurately labels etomidate as safe in acute intermittent porphyria, contradicting most modern drug-safety lists for porphyria. Thiopental being porphyrinogenic is correct.\nMinimal fix: Either (a) change option C to a clearly porphyria-safe agent (e.g., midazolam) while keeping D as the only porphyrinogenic choice, or (b) change the key and explanation to acknowledge both thiopental and etomidate as unsafe and reframe the question accordingly.\n", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-018", "question": "A 28-year-old female with SLE presents with psychosis, catatonia, and seizures. CSF shows anti-NR2A antibodies. Which specific immunosuppressive regimen is most effective for antibody-mediated neuropsychiatric SLE?", "options": ["High-dose steroids alone", "Cyclophosphamide 500 mg/m² monthly", "Rituximab 375 mg/m² weekly × 4 plus high-dose steroids", "Mycophenolate mofetil 2 g daily", "Intravenous immunoglobulin 2 g/kg monthly"], "answer": "C", "answer_index": 2, "explanation": "Anti-NR2A antibody-mediated neuropsychiatric SLE requires B-cell depletion with rituximab plus high-dose steroids. Steroids alone are insufficient. Cyclophosphamide is less effective for antibody-mediated disease. Mycophenolate is maintenance therapy. IVIG is adjunctive. The combination of rituximab and steroids provides rapid clearance of pathogenic antibodies.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N\\nVerdict on keyed answer: No defensible answer\\nKey stem clues: Young woman with severe neuropsychiatric SLE (psychosis, catatonia, seizures) and CSF anti-NR2A antibodies; question asks for “most effective” immunosuppressive regimen for antibody-mediated neuropsychiatric SLE. Options include steroids alone, monthly cyclophosphamide, rituximab + steroids, mycophenolate, and IVIG.\\nMain logical issues: In current mainstream practice, severe neuropsychiatric SLE with CNS involvement is typically treated first-line with high-dose glucocorticoids plus IV cyclophosphamide; rituximab is generally second-line/refractory in guidelines and data are mixed. The stem asserts, without support, that rituximab is superior for “antibody-mediated” disease; this is not an established consensus standard. Thus, option B has strong guideline support, and option C is at best experimental/second-line, making the keyed answer not clearly the single best regimen. The question asks “most effective” in general rather than per a specific trial, so no option is clearly defensible as uniquely best.\\nMain medical accuracy issues: Overstates rituximab’s role and understates cyclophosphamide’s efficacy in severe NPSLE.\\nMinimal fix: Modify stem to specify “in a patient with NPSLE refractory to cyclophosphamide and steroids” and/or change key to cyclophosphamide plus high-dose steroids (adjusting options accordingly).\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N\nVerdict on keyed answer: No defensible answer\nKey stem clues: Young woman with severe neuropsychiatric SLE (psychosis, catatonia, seizures) and CSF anti-NR2A antibodies; question asks for “most effective” immunosuppressive regimen for antibody-mediated neuropsychiatric SLE. Options include steroids alone, monthly cyclophosphamide, rituximab + steroids, mycophenolate, and IVIG.\nMain logical issues: In current mainstream practice, severe neuropsychiatric SLE with CNS involvement is typically treated first-line with high-dose glucocorticoids plus IV cyclophosphamide; rituximab is generally second-line/refractory in guidelines and data are mixed. The stem asserts, without support, that rituximab is superior for “antibody-mediated” disease; this is not an established consensus standard. Thus, option B has strong guideline support, and option C is at best experimental/second-line, making the keyed answer not clearly the single best regimen. The question asks “most effective” in general rather than per a specific trial, so no option is clearly defensible as uniquely best.\nMain medical accuracy issues: Overstates rituximab’s role and understates cyclophosphamide’s efficacy in severe NPSLE.\nMinimal fix: Modify stem to specify “in a patient with NPSLE refractory to cyclophosphamide and steroids” and/or change key to cyclophosphamide plus high-dose steroids (adjusting options accordingly).", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-019", "question": "A 78-year-old female with major depressive disorder is started on sertraline 50 mg daily. She has SIADH risk factors: age >65, female, concomitant thiazide diuretic. Which electrolyte monitoring protocol is recommended?", "options": ["Baseline sodium only", "Baseline and 1-week sodium", "Baseline, 1-week, and 2-week sodium", "Baseline, 1-week, 2-week, and 4-week sodium", "Weekly sodium for 8 weeks"], "answer": "D", "answer_index": 3, "explanation": "SIADH from SSRIs typically occurs within 2-4 weeks. High-risk patients (elderly, female, diuretic use) require sodium monitoring at baseline, 1, 2, and 4 weeks. More frequent monitoring is unnecessary if stable. Baseline alone or single follow-up is insufficient. Weekly monitoring for 8 weeks is excessive and not guideline-recommended.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 78-year-old woman, major depressive disorder, initiation of sertraline, clear SIADH risk factors (elderly, female, thiazide). The question asks for an appropriate sodium monitoring protocol in a clearly high-risk patient starting an SSRI. SSRI-induced SIADH most often occurs within the first 2–4 weeks after initiation, so checking serum sodium at baseline and periodically during this window is appropriate. Among the options, D (baseline, 1-week, 2-week, and 4-week sodium) best covers the highest-risk period with reasonable frequency. A–C provide inadequate duration or frequency of monitoring for a clearly high-risk patient; E is more intensive and longer than typically recommended and is described in the rationale as not guideline-supported. The teaching point (early SIADH risk window and need for closer sodium monitoring in high-risk elderly patients on SSRIs and thiazides) is medically accurate and consistent with commonly cited expert recommendations, even though explicit formal guidelines are limited. Minimal fix: explicitly state in the stem that local institutional protocol recommends sodium checks at baseline and at 1, 2, and 4 weeks in high-risk SSRI starts to anchor the answer in a stated standard.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 78-year-old woman, major depressive disorder, initiation of sertraline, clear SIADH risk factors (elderly, female, thiazide). The question asks for an appropriate sodium monitoring protocol in a clearly high-risk patient starting an SSRI. SSRI-induced SIADH most often occurs within the first 2–4 weeks after initiation, so checking serum sodium at baseline and periodically during this window is appropriate. Among the options, D (baseline, 1-week, 2-week, and 4-week sodium) best covers the highest-risk period with reasonable frequency. A–C provide inadequate duration or frequency of monitoring for a clearly high-risk patient; E is more intensive and longer than typically recommended and is described in the rationale as not guideline-supported. The teaching point (early SIADH risk window and need for closer sodium monitoring in high-risk elderly patients on SSRIs and thiazides) is medically accurate and consistent with commonly cited expert recommendations, even though explicit formal guidelines are limited. Minimal fix: explicitly state in the stem that local institutional protocol recommends sodium checks at baseline and at 1, 2, and 4 weeks in high-risk SSRI starts to anchor the answer in a stated standard.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-020", "question": "A 35-year-old male in a personal injury lawsuit reports severe chronic pain despite normal examinations and imaging. He is observed to be inconsistent in his symptom presentation between evaluations. Which specific criterion best distinguishes malingering from factitious disorder in this scenario?", "options": ["Presence of secondary gain", "Intentional production of symptoms", "Lack of insight into psychological factors", "Symptoms are under voluntary control", "Absence of medical explanation"], "answer": "A", "answer_index": 0, "explanation": "Both malingering and factitious disorder involve intentional symptom production. The key distinction is motivation: malingering seeks external reward (money, avoiding work), while factitious disorder seeks the 'sick role' for psychological needs. Both have insight and voluntary control. Absence of medical explanation is common to both somatic symptom disorders.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Adult in a personal injury lawsuit, reporting severe chronic pain with normal exams and imaging, plus inconsistent symptom presentation. The question explicitly asks for the criterion that distinguishes malingering from factitious disorder. The explanation notes that both involve intentional symptom production and voluntary control of symptoms; the differentiating feature is the presence of external incentives (secondary gain) in malingering.\\nOption A (Presence of secondary gain) correctly identifies external incentives (lawsuit, financial gain) as the distinguishing motivation for malingering versus factitious disorder, which is driven by internal psychological need for the sick role. Option B (Intentional production of symptoms) and D (Symptoms are under voluntary control) apply to both malingering and factitious disorder, so they are not discriminating. Option C (Lack of insight into psychological factors) is not a standard differentiating criterion. Option E (Absence of medical explanation) is nonspecific and seen in many somatic presentations.\\nMain medical accuracy issues: None; the teaching point is standard DSM/board-level psych knowledge.\\nMinimal fix: Add a brief phrase in the stem highlighting the ongoing legal/financial incentive (e.g., “seeking a large financial settlement”) to make the external secondary gain more explicit.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Adult in a personal injury lawsuit, reporting severe chronic pain with normal exams and imaging, plus inconsistent symptom presentation. The question explicitly asks for the criterion that distinguishes malingering from factitious disorder. The explanation notes that both involve intentional symptom production and voluntary control of symptoms; the differentiating feature is the presence of external incentives (secondary gain) in malingering.\nOption A (Presence of secondary gain) correctly identifies external incentives (lawsuit, financial gain) as the distinguishing motivation for malingering versus factitious disorder, which is driven by internal psychological need for the sick role. Option B (Intentional production of symptoms) and D (Symptoms are under voluntary control) apply to both malingering and factitious disorder, so they are not discriminating. Option C (Lack of insight into psychological factors) is not a standard differentiating criterion. Option E (Absence of medical explanation) is nonspecific and seen in many somatic presentations.\nMain medical accuracy issues: None; the teaching point is standard DSM/board-level psych knowledge.\nMinimal fix: Add a brief phrase in the stem highlighting the ongoing legal/financial incentive (e.g., “seeking a large financial settlement”) to make the external secondary gain more explicit.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]